Sökning: WFRF:(Berglund Åke)
> (2015-2019) >
Reduced-dose combin...
-
Whither, Stine BraendegaardOdense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark;Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark;Univ Southern Denmark, Dept Clin Res, Odense, Denmark
(författare)
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
ELSEVIER INC,2019
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-382373
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-382373URI
-
https://doi.org/10.1016/S2468-1253(19)30041-XDOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:140663456URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Older or vulnerable patients with metastatic colorectal cancer are seldom included in randomised trials.The multicentre NORDIC9 trial evaluated reduced-dose combination chemotherapy compared with full-dose monotherapy in older, vulnerable patients.Methods: This randomised, open-label phase 2 trial was done in 23 Nordic oncology clinics and included patients aged 70 years or older with previously untreated metastatic colorectal cancer who were not candidates for full-dose combination chemotherapy. Patients were block randomised (1: 1) using a web-based tool to full-dose S-1 (30 mg/m(2) orally twice daily on days 1-14 every 3 weeks) followed by second-line treatment at progression with irinotecan (250 mg/m(2) intravenously on day 1 every 3 weeks or 180 mg/m(2) intravenously on day 1 every 2 weeks) or reduceddose combination chemotherapy with S-1 (20 mg/m(2) orally twice daily on days 1-14) and oxaliplatin (100 mg/m(2) intravenously on day 1 every 3 weeks) followed by second-line treatment at progression with S-1 (20 mg/m(2) orally twice daily on days 1-14) and irinotecan (180 mg/m(2) intravenously on day 1 every 3 weeks). Use of bevacizumab (7.5 mg/kg intravenously on day 1 of each cycle) was optional. Treatment allocation was not masked and randomisation was stratified for institution and bevacizumab. The primary outcome was progression-free survival. Survival analyses were by intention to treat and safety analyses were done on the treated population. This trial is registered with EudraCT, number 2014-000394-39, and is closed to new participants.Findings: From March 9, 2015, to Oct 11, 2017, 160 patients with a median age of 78 years (IQR 76-81) were randomly assigned to full-dose monotherapy (n=83) or reduced-dose combination chemotherapy (n=77). At data cutoff (Sept 1, 2018; median follow-up 23.8 months [IQR 18.8-30.9]), 81 (98%) patients in the full-dose monotherapy group and 71 (92%) patients in the reduced-dose combination group had progressed or died. Median progression-free survival was significantly longer with reduced-dose combination chemotherapy (6.2 months [95% CI 5.3-8.3]) than with full-dose monotherapy (5.3 months [4.1-6.8]; hazard ratio [HR] 0.72 [95% CI 0.52-0.99]; p=0.047). Toxicity was evaluated in 157 patients who received treatment. Significantly more patients in the full-dose monotherapy group (51 [62%] of 82 patients) experienced at least one grade 3-4 adverse event than in the reduced-dose combination group (32 [43%] of 75 patients; p=0.014). Grade 3-4 diarrhoea (12 [15%] vs two [3%]; p=0.018), fatigue (ten [12%] vs three [4%]; p=0.083), and dehydration (five [6%] vs none; p=0.060) were more frequent in the full-dose monotherapy group than in the reduced-dose combination group. Treatment-related deaths occurred in three patients during firstline treatment and three patients during second-line treatment (two in the full-dose monotherapy group vs one in the reduced-dose combination group in both cases).Interpretation: Reduced-dose combination chemotherapy with S-1 and oxaliplatin for older, vulnerable patients with metastatic colorectal cancer was more effective and resulted in less toxicity than full-dose monotherapy with S-1. Reduced-dose combination chemotherapy could be a preferred treatment for this population.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Liposits, GaborHaukeland Hosp, Dept Oncol, Bergen, Norway
(författare)
-
Skuladottir, HaifaReg Hosp West Jutland, Dept Oncol, Herning, Denmark
(författare)
-
Hofsli, EvaTrondheim Reg & Univ Hosp, Dept Oncol, Trondheim, Norway
(författare)
-
Shah, Carl-HenrikKarolinska Institutet
(författare)
-
Poulsen, Laurids ÖstergaardAalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
(författare)
-
Ryg, JesperOdense Univ Hosp, Dept Geriatr Med, Odense, Denmark;Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark;Univ Southern Denmark, Dept Clin Res, Odense, Denmark
(författare)
-
Osterlund, PiaTampere Univ, Tampere Univ Hosp, Dept Oncol, Tampere, Finland;Univ Helsinki, Dept Oncol, Helsinki Univ Hosp, Helsinki, Finland
(författare)
-
Berglund, ÅkeUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)akebergl
(författare)
-
Qvortrup, CamillaOdense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark;Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark
(författare)
-
Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim
(författare)
-
Sorbye, HalfdanHaukeland Hosp, Dept Oncol, Bergen, Norway
(författare)
-
Pfeiffer, PerOdense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark;Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark;Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN, Odense, Denmark;Univ Southern Denmark, Dept Clin Res, Odense, Denmark
(författare)
-
Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark;Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark;Univ Southern Denmark, Dept Clin Res, Odense, DenmarkHaukeland Hosp, Dept Oncol, Bergen, Norway
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:The Lancet Gastroenterology & Hepatology: ELSEVIER INC4:5, s. 376-3882468-1253
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Whither, Stine B ...
-
Liposits, Gabor
-
Skuladottir, Hai ...
-
Hofsli, Eva
-
Shah, Carl-Henri ...
-
Poulsen, Laurids ...
-
visa fler...
-
Ryg, Jesper
-
Osterlund, Pia
-
Berglund, Åke
-
Qvortrup, Camill ...
-
Glimelius, Bengt
-
Sorbye, Halfdan
-
Pfeiffer, Per
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
The Lancet Gastr ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet